Skip to main
SLP

Simulations Plus (SLP) Stock Forecast & Price Target

Simulations Plus (SLP) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Simulations Plus Inc. has demonstrated strong organizational growth, with an impressive 30% increase in the total dollar value of awarded work not yet recognized in backlog in Q3 year-over-year. The company has also experienced notable improvements in proposal activity within the biotech sector, signaling increased confidence among clients as they navigate their budgeting cycles. Additionally, the software segment reported a substantial 22% year-over-year revenue increase, alongside a modest growth in services revenue, highlighting the company's robust position in the pharmaceutical research software market.

Bears say

Simulations Plus Inc reported a year-over-year revenue decline of 6% in F4Q:25, despite a full-year increase of 13%, indicating potential underlying weakness in its business model. The company's guidance for F1Q:26 anticipates further revenue decline of 3% to 5%, which raises concerns about its ability to maintain growth relative to competitors in the pharmaceutical technology sector. Additionally, the organic growth rate has been stagnant, with growth of only 5% in the first half of the fiscal year followed by declines of 3% and 6.5% in the latter quarters, signaling a troubling trend for the company's revenue trajectory.

Simulations Plus (SLP) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Simulations Plus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Simulations Plus (SLP) Forecast

Analysts have given Simulations Plus (SLP) a Buy based on their latest research and market trends.

According to 5 analysts, Simulations Plus (SLP) has a Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Simulations Plus (SLP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.